

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immunoncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immunoncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management

Jun 13 2018, 8:00 AM EDT

BioXcel Therapeutics Appoints Vincent J. O'Neill M.D., as Senior Vice President and Chief Medical Officer

Jun 7 2018, 8:00 AM EDT

BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Jun 5 2018, 8:00 AM EDT

Stock Overview

Symbol	BTAI
Exchange	Nasdaq
Market Cap	142.06m
Last Price	\$9.08
52-Week	\$6.76 - \$11.94

06/21/2018 04:00 PM EDT

Investor Relations

Lee Roth
T: 646-536-7012
lroth@theruthgroup.com

Management Team

Vimal Mehta, Ph.D.

CEO & Founder

Frank D. Yocca, Ph.D.

Chief Scientific Officer

Vincent J.O'Neill M.D.

Senior Vice President and Chief Medical Officer

Richard I. Steinhart

VP & CFO

Chids Mahadevan

VP, Finance & Chief Accounting Officer

Cedric Burg, PhD

VP, Head of Global Clinical Operations and Project Management

BioXcel Therapeutics, Inc.

780 East Main Street
Branford, CT 06405

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.